

32692

Customer Number

Case No.: 58210US004

Patent

IFW  
\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Named Inventor: FINK, JASON R.

Application No.: 10/788731

Group Art Unit: 1644

Filed: February 27, 2004

Examiner: Unknown

Title: SELECTIVE MODULATION OF TLR-MEDIATED BIOLOGICAL ACTIVITY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR § 1.8(a)]

I hereby certify that this correspondence is being:

- ☒ deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
- ☐ transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at 571-273-8300.

23 Nov. 2005

Date

Laci Burhop

Signed by: Laci Burhop

Dear Sir:

Pursuant to 37 CFR §§ 1.56, 1.97, and 1.98, enclosed is a completed Form PTO-1449, citing references submitted for consideration by the Examiner. It is respectfully requested that the Examiner initial and return the enclosed Form PTO-1449 to indicate that each reference has been considered.

Copies of any cited foreign patents, foreign publications, non-patent literature documents, and any pending U.S. applications filed before June 30, 2003, are enclosed. Copies of any pending U.S. applications filed after June 30, 2003 that can be accessed on the USPTO's IFW system are not enclosed as per USPTO Waiver dated September 21, 2004. Copies of any U.S. patents and published U.S. patent applications are not enclosed.

11/29/2005 MWOLDGE1 00000030 133723 10788731

01 FC:1806

180.00 DA

If a first Office Action on the merits has been mailed prior to the mailing date of this document, please charge the fee for consideration of an Information Disclosure Statement set forth in 37 CFR § 1.17(p), and if necessary, please charge any additional fees, or credit any overpayment to Deposit Account No. 13-3723.

Respectfully submitted,

11/23/2005  
Date

By: Christopher D. Gram  
Christopher D. Gram, Reg. No.: 43,643  
Telephone No.: 651-733-1507

Office of Intellectual Property Counsel  
3M Innovative Properties Company  
Facsimile No.: 651-736-3833

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Page 1 of 1

**Application Number****10/788731****Filing Date****February 27, 2004****First Named Inventor****Fink, Jason R.****Art Unit****1644****Examiner Name****Unknown****Attorney Case Number****58210US004****U.S. Patent Documents**

Exam. Init.*	Cite No.	Document Number	Publication Date or Issue Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Doc. Number-(Kind Code if Known)			
	A1	US-			
	A2	US-			
	A3	US-			
	A4	US-			
	A5	US-			
	A6	US-			
	A7	US-			
	A8	US-			

**Foreign Patent Documents**

Exam. Init.*	Cite No.	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation (Check if yes)
		Ctry. Code	Number-KindCode (If known)				
	B1						
	B2						
	B3						
	B4						
	B5						
	B6						
	B7						

**OTHER DOCUMENTS**

Exam. Init.*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Translation (Check if yes)
	C1	Gorden et al., "Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8", <u>The Journal of Immunology</u> , 2005, Vol. 174, pgs. 1259-1268.	
	C2	Sauder et al., "Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults", <u>Antimicrobial Agents and Chemotherapy</u> , December 2003, Vol. 47, No. 12, pgs. 3846-3852.	
	C3		

**\*Examiner:****Date Considered:**

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Information Disclosure Statement)*